481 related articles for article (PubMed ID: 9131486)
1. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson GR
J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
[TBL] [Abstract][Full Text] [Related]
2. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo drug interactions involving human CYP3A.
Thummel KE; Wilkinson GR
Annu Rev Pharmacol Toxicol; 1998; 38():389-430. PubMed ID: 9597161
[TBL] [Abstract][Full Text] [Related]
4. Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression.
Berg-Candolfi M; Candolfi E; Benet LZ
Xenobiotica; 1996 Apr; 26(4):381-94. PubMed ID: 9173679
[TBL] [Abstract][Full Text] [Related]
5. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Wright CE; Shader RI
J Clin Psychopharmacol; 1996 Apr; 16(2):104-12. PubMed ID: 8690825
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
[TBL] [Abstract][Full Text] [Related]
8. Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo.
Goldberg MJ; Ring B; DeSante K; Cerimele B; Hatcher B; Sides G; Wrighton S
J Clin Pharmacol; 1996 Dec; 36(12):1154-60. PubMed ID: 9013373
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.
Raeissi SD; Guo Z; Dobson GL; Artursson P; Hidalgo IJ
Pharm Res; 1997 Aug; 14(8):1019-25. PubMed ID: 9279883
[TBL] [Abstract][Full Text] [Related]
10. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine.
Lampen A; Zhang Y; Hackbarth I; Benet LZ; Sewing KF; Christians U
J Pharmacol Exp Ther; 1998 Jun; 285(3):1104-12. PubMed ID: 9618413
[TBL] [Abstract][Full Text] [Related]
12. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
13. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
[TBL] [Abstract][Full Text] [Related]
14. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
15. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
16. Can oral midazolam predict oral cyclosporine disposition?
Paine MF; Davis CL; Shen DD; Marsh CL; Raisys VA; Thummel KE
Eur J Pharm Sci; 2000 Nov; 12(1):51-62. PubMed ID: 11121733
[TBL] [Abstract][Full Text] [Related]
17. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
19. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting the clinical development of cytochrome p450 3A substrates.
Gibbs MA; Hosea NA
Clin Pharmacokinet; 2003; 42(11):969-84. PubMed ID: 12908853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
